- Third Quarter Net Sales of $95 Million-
Depomed, Inc. (Nasdaq:DEPO) today reported financial results for
the quarter ended September 30, 2017 and provided an update to the
business.
“During the third quarter, we made progress in stabilizing our
business despite the declines in the opioid market. We would have
expected to have made further progress in the fourth quarter if not
for the negative impact of NUCYNTA supply issues following
Hurricanes Irma and Maria,” said Arthur Higgins, President and CEO
of Depomed. “With September’s expansion of the neurology salesforce
and today’s exciting transaction with Slán Medicinal Holdings, we
see our go forward growth based on three pillars comprised of
maintaining a strong NUCYNTA franchise, growing our neurology
franchise and building a new specialty business. At the core of
this strategy is delivering value to our stakeholders while always
putting the patient first.”
Business and Financial Highlights
- Third quarter 2017 revenues were $95 million
- Third quarter ending cash and marketable securities was $113
million
- Quarterly GAAP net loss of ($16) million or ($0.25) per
share
- Quarterly non-GAAP adjusted earnings of $10 million, or $0.14
per share
- Quarterly non-GAAP adjusted EBITDA of $30 million
- Neurology Salesforce increased to 90 representatives effective
September 1
- Acquisition of rights to Cosyntropin (Synthetic ACTH Depot)
creates new specialty business
- Lazanda Sale to Slán Medicinal Holdings reduces our
concentration in the opioid market
|
|
|
|
|
|
|
|
|
|
REVENUES (GAAP BASIS) |
|
(in thousands, unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Nine Months Ended |
|
|
|
September 30, |
|
September 30, |
|
|
|
|
2017 |
|
|
2016 |
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
Product
sales, net: |
|
|
|
|
|
|
|
|
|
Nucynta
products |
|
$ |
58,665 |
|
$ |
65,287 |
|
$ |
183,299 |
|
|
$ |
206,568 |
|
Gralise |
|
|
21,103 |
|
|
20,640 |
|
|
57,777 |
|
|
|
63,451 |
|
Cambia |
|
|
8,164 |
|
|
9,110 |
|
|
23,862 |
|
|
|
22,900 |
|
Lazanda |
|
|
4,040 |
|
|
8,181 |
|
|
13,239 |
|
|
|
19,093 |
|
Zipsor |
|
|
3,232 |
|
|
7,085 |
|
|
12,286 |
|
|
|
19,379 |
|
Pharmacy
benefit manager dispute reserve |
|
|
- |
|
|
- |
|
|
(4,742 |
) |
|
|
- |
|
Total product sales, net |
|
|
95,204 |
|
|
110,303 |
|
|
285,721 |
|
|
|
331,391 |
|
|
|
|
|
|
|
|
|
|
|
Royalties |
|
|
209 |
|
|
221 |
|
|
596 |
|
|
|
595 |
|
|
|
|
|
|
|
|
|
|
|
Total revenues (GAAP Basis) |
|
$ |
95,413 |
|
$ |
110,524 |
|
$ |
286,317 |
|
|
$ |
331,986 |
|
|
|
|
|
|
|
|
|
|
|
Transformational Transaction Creates New Specialty
Business
This afternoon the Company announced that it has entered into an
agreement with Slán Medicinal Holdings. (“Slán”), pursuant to which
the Company acquired from Slán the rights to market the specialty
drug, Cosyntropin (Synthetic ACTH Depot), in the United States and
divested its Lazanda® (nasal fentanyl) to Slán. The Company expects
Slán to submit a New Drug Application with the U.S. Food and Drug
Administration for the first indication for Cosyntropin (Synthetic
ACTH Depot) in late 2018.
Executed Expansion of Neurology Salesforce
As of September 1st, the Company completed the growth of its
Neurology salesforce to 90 representatives who are focused on
Gralise® and CAMBIA®. The Company believes that the increased
salesforce, with smaller and more targeted territories, will
benefit these highly promotionally sensitive products. The Company
also believes that the increased salesforce provides a platform
that allows for the potential addition of neurology-based product
acquisitions.
Puerto Rico Product Supply Update
Based on the information available to the Company at this time,
the Company will experience temporary outages of certain
strengths of NUCYNTA ER in the fourth quarter. The Company expects
that based on our current inventory and our manufacturer’s
potential ability to produce new drug supply that the magnitude of
the outages will be less than $10 million.
NUCYNTA IR recently transitioned to a new third party
manufacturer in the United States, and based on currently available
information, the Company does not anticipate any material
disruption to this supply. In addition, based on the information
available at this time, the Company believes it has an adequate
inventory of Gralise, which is manufactured in Puerto
Rico.
Updated 2017 Financial Outlook The Company is
updating its 2017 financial guidance as a result of third quarter
performance, the impact of Hurricanes Irma and Maria to the supply
of NUCYNTA®, continuing contraction in the long-acting and
short-acting opioid markets and the transfer of Lazanda to Slán
Medicinal Holdings.
|
Updated Guidance |
Prior Guidance |
Total Revenue (GAAP) |
$375 to $380 million |
$395 to $410 million |
Total Revenue (Non-GAAP) |
$380 to $385 million |
$400 to $415 million |
Non-GAAP SG&A Expense |
$190 to $194 million |
$195 to $201 million |
Non-GAAP R&D Expense |
$14 to $16 million |
$18 to $23 million |
Non-GAAP Adjusted EBITDA |
$104 to $109 million |
$107 to $117 million |
Non-GAAP Financial Measures
To supplement our financial results presented on a U.S.
generally accepted accounting principles, or GAAP, basis, we have
included information about non‑GAAP adjusted earnings, non‑GAAP
adjusted earnings per share and non-GAAP adjusted EBITDA, non‑GAAP
financial measures, as useful operating metrics. We believe that
the presentation of these non‑GAAP financial measures, when viewed
with our results under GAAP and the accompanying reconciliation,
provides supplementary information to analysts, investors, lenders,
and our management in assessing the Company’s performance and
results from period to period. We use these non‑GAAP measures
internally to understand, manage and evaluate the Company’s
performance, and in part, in the determination of bonuses for
executive officers and employees. These non‑GAAP financial measures
should be considered in addition to, and not a substitute for, or
superior to, net income or other financial measures calculated in
accordance with GAAP. Non‑GAAP adjusted earnings and non‑GAAP
adjusted earnings per share are not based on any standardized
methodology prescribed by GAAP and represent GAAP net income (loss)
and GAAP earnings (loss) per share adjusted to exclude
amortization, IPR&D and non‑cash adjustments related to product
acquisitions, stock‑based compensation expense, non‑cash interest
expense related to debt, costs associated with the special
meeting requests made by an activist investor and CEO transition,
costs associated with an attempted debt refinancing, restructuring
costs, adjustments associated with non-recurring legal settlements
and disputes, and to adjust for the tax effect related to each of
the non-GAAP adjustments. Non‑GAAP adjusted EBITDA is not based on
any standardized methodology prescribed by GAAP and represents GAAP
net income (loss) adjusted to exclude interest income, interest
expense, amortization, IPR&D and non‑cash adjustments related
to product acquisitions, stock‑based compensation expense,
depreciation, taxes, restructuring costs, adjustments related to
non-recurring legal settlements and disputes, costs associated with
an attempted debt refinancing, the special meeting requests made by
an activist investor, and CEO transition. Non‑GAAP financial
measures used by us may be calculated differently from, and
therefore may not be comparable to, non‑GAAP measures used by other
companies.
Conference Call and Webcast
Depomed will host a conference call today, Tuesday, November 7th
beginning at 4:30 p.m. EST (1:30 p.m. PST) to discuss its results.
This event can be accessed in three ways:
- From the Depomed website: http://investor.depomedinc.com/
Please access the website 15 minutes prior to the start of the call
to download and install any necessary audio software.
- By telephone: Participants can access the call by dialing (866)
643-3010 (United States) or (857) 270-6032 (International)
referencing Conference ID 8996849.
- By replay: A replay of the webcast will be located under the
Investor Relations section of Depomed's website approximately two
hours after the conclusion of the live call and will be available
for three months.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on
enhancing the lives of the patients, families, physicians,
providers and payors we serve through commercializing innovative
products for pain and neurology related disorders. Depomed markets
five medicines with areas of focus that include mild to severe
acute pain, moderate to severe chronic pain, neuropathic pain and
migraine. Depomed is headquartered in Newark, California. To learn
more about Depomed, visit www.depomed.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995. The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties including, but not limited to,
those related to the commercialization of NUCYNTA ER, NUCYNTA,
Gralise, CAMBIA, Zipsor and Lazanda, Depomed's financial outlook
for 2017 and expectations regarding financial results and potential
business opportunities and other risks detailed in the Company's
Securities and Exchange Commission filings, including the Company's
most recent Annual Report on Form 10-K and most recent Quarterly
Report on Form 10-Q. The achievement of 2017 financial guidance is
significantly dependent upon the success of NUCYNTA ER and NUCYNTA,
and the continuing public focus on the opioid markets and the
decline in the short-acting and long-acting opioid markets present
risk to achievement of financial guidance. The inclusion of
forward-looking statements should not be regarded as a
representation that any of the Company's plans or objectives will
be achieved. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
The Company undertakes no obligation to publicly release the result
of any revisions to these forward-looking statements that may be
made to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
INVESTOR AND MEDIA CONTACT:
Christopher Keenan VP, Investor Relations and Corporate
Communications 510-744-8000 ckeenan@depomed.com
|
|
|
|
|
|
|
|
|
|
CONSOLIDATED STATEMENTS OF OPERATIONS (GAAP
BASIS) |
|
(in thousands, except per share
amounts) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Nine Months Ended |
|
|
|
September 30, |
|
September 30, |
|
|
|
|
2017 |
|
|
|
2016 |
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
(unaudited) |
|
(unaudited) |
|
Revenues: |
|
|
|
|
|
|
|
|
|
Product
sales, net |
|
$ |
95,204 |
|
|
$ |
110,303 |
|
|
$ |
285,721 |
|
|
$ |
331,391 |
|
|
Royalties |
|
|
209 |
|
|
|
221 |
|
|
|
596 |
|
|
|
595 |
|
|
Total
revenues |
|
|
95,413 |
|
|
|
110,524 |
|
|
|
286,317 |
|
|
|
331,986 |
|
|
|
|
|
|
|
|
|
|
|
|
Costs and
expenses: |
|
|
|
|
|
|
|
|
|
Cost of
sales |
|
|
17,396 |
|
|
|
20,243 |
|
|
|
54,895 |
|
|
|
64,757 |
|
|
Research
and development expense |
|
|
1,761 |
|
|
|
10,412 |
|
|
|
12,459 |
|
|
|
23,477 |
|
|
Selling,
general and administrative expense |
|
|
48,850 |
|
|
|
51,574 |
|
|
|
147,379 |
|
|
|
156,036 |
|
|
Amortization of intangible assets |
|
|
25,734 |
|
|
|
27,037 |
|
|
|
77,204 |
|
|
|
81,111 |
|
|
Restructuring charges |
|
|
434 |
|
|
|
- |
|
|
|
3,875 |
|
|
|
- |
|
|
Total
costs and expenses |
|
|
94,175 |
|
|
|
109,266 |
|
|
|
295,812 |
|
|
|
325,381 |
|
|
|
|
|
|
|
|
|
|
|
|
Loss from
operations |
|
|
1,238 |
|
|
|
1,258 |
|
|
|
(9,495 |
) |
|
|
6,605 |
|
|
Interest
and other income |
|
|
72 |
|
|
|
113 |
|
|
|
604 |
|
|
|
310 |
|
|
Loss on
prepayment of senior notes |
|
|
- |
|
|
|
- |
|
|
|
(5,364 |
) |
|
|
(5,777 |
) |
|
Interest
expense |
|
|
(17,815 |
) |
|
|
(20,307 |
) |
|
|
(55,697 |
) |
|
|
(63,182 |
) |
|
(Provision for)/Benefit from income taxes |
|
|
513 |
|
|
|
6,042 |
|
|
|
560 |
|
|
|
17,692 |
|
|
Net
loss |
|
$ |
(15,992 |
) |
|
$ |
(12,894 |
) |
|
$ |
(69,392 |
) |
|
$ |
(44,352 |
) |
|
|
|
|
|
|
|
|
|
|
|
Basic and
diluted net loss per share |
|
$ |
(0.25 |
) |
|
$ |
(0.21 |
) |
|
$ |
(1.11 |
) |
|
$ |
(0.73 |
) |
|
Shares
used in calculating basic and diluted net loss per share |
|
|
62,997 |
|
|
|
61,422 |
|
|
|
62,556 |
|
|
|
61,163 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONSOLIDATED CONDENSED BALANCE
SHEETS |
|
|
(in thousands) |
|
|
(unaudited) |
|
|
|
|
September 30, |
|
December 31, |
|
|
|
|
|
2017 |
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash,
cash equivalents and marketable securities |
|
$ |
113,457 |
|
$ |
177,420 |
|
|
Accounts
receivable |
|
|
77,698 |
|
|
102,589 |
|
|
Inventories |
|
|
10,415 |
|
|
13,033 |
|
|
Property
and equipment, net |
|
|
13,943 |
|
|
15,526 |
|
|
Intangible assets, net |
|
|
824,944 |
|
|
902,149 |
|
|
Prepaid
and other assets |
|
|
19,050 |
|
|
14,620 |
|
|
Total
assets |
|
$ |
1,059,507 |
|
$ |
1,225,337 |
|
|
|
|
|
|
|
|
|
Accounts
payable |
|
|
7,033 |
|
|
14,855 |
|
|
Income
tax payable |
|
|
28 |
|
|
59 |
|
|
Interest
payable |
|
|
11,308 |
|
|
15,924 |
|
|
Accrued
liabilities |
|
|
47,599 |
|
|
59,398 |
|
|
Accrued
rebates, returns and discounts |
|
|
136,998 |
|
|
131,536 |
|
|
Senior
notes |
|
|
369,226 |
|
|
466,051 |
|
|
Convertible notes |
|
|
265,163 |
|
|
252,725 |
|
|
Contingent consideration liability |
|
|
5,636 |
|
|
14,825 |
|
|
Other
liabilities |
|
|
17,869 |
|
|
19,176 |
|
|
Shareholders’ equity |
|
|
198,647 |
|
|
250,788 |
|
|
Total
liabilities and shareholders’ equity |
|
|
1,059,507 |
|
$ |
1,225,337 |
|
|
|
|
|
|
|
|
|
RECONCILIATION OF GAAP NET LOSS TO NON-GAAP
ADJUSTED EARNINGS |
|
|
(in thousands, except per share
amounts) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Nine Months Ended |
|
|
|
|
September 30, |
|
September 30, |
|
|
|
|
|
2017 |
|
|
|
2016 |
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
(unaudited) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net
loss |
|
$ |
(15,992 |
) |
|
$ |
(12,894 |
) |
|
$ |
(69,392 |
) |
|
$ |
(44,352 |
) |
|
|
Non-cash interest expense on debt |
|
|
4,839 |
|
|
|
4,460 |
|
|
|
15,613 |
|
|
|
13,861 |
|
|
|
Managed care dispute reserve |
|
|
- |
|
|
|
- |
|
|
|
4,742 |
|
|
|
- |
|
|
|
Intangible amortization related to product acquisitions |
|
|
25,734 |
|
|
|
27,037 |
|
|
|
77,204 |
|
|
|
81,111 |
|
|
|
Inventory step-up related to product acquisitions |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
16 |
|
|
|
Contingent consideration related to product acquisitions |
|
|
(1,194 |
) |
|
|
686 |
|
|
|
(6,525 |
) |
|
|
1,593 |
|
|
|
Stock based compensation |
|
|
2,911 |
|
|
|
4,364 |
|
|
|
9,870 |
|
|
|
12,602 |
|
|
|
Other costs (1) |
|
|
612 |
|
|
|
2,015 |
|
|
|
3,142 |
|
|
|
2,942 |
|
|
|
Restructuring charges |
|
|
434 |
|
|
|
- |
|
|
|
3,875 |
|
|
|
- |
|
|
|
Valuation allowance on deferred tax assets |
|
|
4,172 |
|
|
|
- |
|
|
|
19,274 |
|
|
|
- |
|
|
|
Income tax effect of non-GAAP adjustments (3) |
|
|
(11,846 |
) |
|
|
(13,479 |
) |
|
|
(38,249 |
) |
|
|
(39,211 |
) |
|
|
Non-GAAP
adjusted earnings |
|
$ |
9,670 |
|
|
$ |
12,189 |
|
|
$ |
19,554 |
|
|
$ |
28,562 |
|
|
|
Add
interest expense of convertible debt, net of tax (2) |
|
|
1,348 |
|
|
|
1,348 |
|
|
|
2,695 |
|
|
|
2,695 |
|
|
|
Numerator |
|
$ |
11,018 |
|
|
$ |
13,537 |
|
|
$ |
22,249 |
|
|
$ |
31,257 |
|
|
|
Shares
used in calculation (2) |
|
|
81,376 |
|
|
|
81,940 |
|
|
|
81,607 |
|
|
|
81,370 |
|
|
|
Non-GAAP
adjusted earnings per share |
|
$ |
0.14 |
|
|
$ |
0.17 |
|
|
$ |
0.27 |
|
|
$ |
0.38 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Other costs represents non-recurring costs
associated with the special meeting requests of an activist
investor, CEO transition and an attempted debt refinancing. |
|
|
(2) The Company uses the if-converted method to compute
diluted earnings per share with respect to its convertible
debt. |
|
|
(3) Calculated by taking the pre-tax non-GAAP
adjustments and applying the statutory tax rate. Expected
cash taxes were zero for the three months ended September 30, 2017
and $(1,303) for the three months ended September 30, 2016.
Expected cash taxes were zero for the nine months ended September
30, 2017 and $1,509 for the nine months ended September 30,
2016. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RECONCILIATION OF GAAP NET LOSS TO NON-GAAP
ADJUSTED EBITDA |
|
|
(in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Nine Months Ended |
|
|
|
|
September 30, |
|
September 30, |
|
|
|
|
|
2017 |
|
|
|
2016 |
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
(unaudited) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net
loss |
|
$ |
(15,992 |
) |
|
$ |
(12,894 |
) |
|
$ |
(69,392 |
) |
|
$ |
(44,352 |
) |
|
|
Pharmacy benefit manager dispute reserve |
|
|
- |
|
|
|
- |
|
|
|
4,742 |
|
|
|
- |
|
|
|
Intangible amortization related to product acquisitions |
|
|
25,734 |
|
|
|
27,037 |
|
|
|
77,204 |
|
|
|
81,111 |
|
|
|
Inventory step-up related to product acquisitions |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
16 |
|
|
|
Contingent consideration related to product acquisitions |
|
|
(1,194 |
) |
|
|
686 |
|
|
|
(6,525 |
) |
|
|
1,593 |
|
|
|
Stock based compensation |
|
|
2,911 |
|
|
|
4,364 |
|
|
|
9,870 |
|
|
|
12,602 |
|
|
|
Interest income |
|
|
(72 |
) |
|
|
(113 |
) |
|
|
(332 |
) |
|
|
(310 |
) |
|
|
Interest expense |
|
|
17,584 |
|
|
|
19,666 |
|
|
|
59,829 |
|
|
|
67,001 |
|
|
|
Depreciation |
|
|
605 |
|
|
|
646 |
|
|
|
1,839 |
|
|
|
1,908 |
|
|
|
Benefit from income taxes |
|
|
(513 |
) |
|
|
(6,042 |
) |
|
|
(560 |
) |
|
|
(17,692 |
) |
|
|
Other costs (1) |
|
|
612 |
|
|
|
2,015 |
|
|
|
3,142 |
|
|
|
2,942 |
|
|
|
Restructuring charges |
|
|
434 |
|
|
|
- |
|
|
|
3,875 |
|
|
|
- |
|
|
|
Transaction costs |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
45 |
|
|
|
Non-GAAP
adjusted EBITDA |
|
$ |
30,109 |
|
|
$ |
35,365 |
|
|
$ |
83,692 |
|
|
$ |
104,864 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Other costs represents non-recurring costs
associated with the special meeting requests of an activist
investor, CEO transition and an attempted debt refinancing. |
|
|
|
|
|
|
|
|
|
|
|
|
|
RECONCILATIONS OF GAAP REPORTED TO NON-GAAP
ADJUSTED INFORMATION |
|
For the three months ended September 30,
2017 |
|
(in thousands) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
Research and development expense |
Selling, general and administrative
expense |
Restructuring Charges |
Amortization of intangible assets |
Interest expense |
Benefit from (provision for) income
taxes |
|
GAAP as reported |
|
$ |
17,396 |
|
$ |
1,761 |
|
$ |
48,850 |
|
$ |
434 |
|
$ |
25,734 |
|
$ |
(17,815 |
) |
$ |
513 |
|
|
Non-cash
interest expense on debt |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
4,839 |
|
|
- |
|
|
Intangible amortization related to product acquisitions |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(25,734 |
) |
|
- |
|
|
- |
|
|
Contingent consideration related to product acquisitions |
|
|
- |
|
|
- |
|
|
1,415 |
|
|
- |
|
|
- |
|
|
221 |
|
|
- |
|
|
Stock
based compensation |
|
|
(9 |
) |
|
(45 |
) |
|
(2,857 |
) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
Other
costs |
|
|
- |
|
|
- |
|
|
(612 |
) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
Restructuring charges |
|
|
- |
|
|
- |
|
|
- |
|
|
(434 |
) |
|
- |
|
|
- |
|
|
- |
|
|
Valuation
allowance on deferred tax assets |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
4,172 |
|
|
Income
tax effect of non-GAAP adjustments |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(11,846 |
) |
|
Non-GAAP
adjusted |
|
$ |
17,387 |
|
$ |
1,716 |
|
$ |
46,796 |
|
$ |
- |
|
$ |
- |
|
$ |
(12,755 |
) |
$ |
(7,161 |
) |
|
|
|
|
|
|
|
|
|
|
|
RECONCILATIONS OF GAAP REPORTED TO NON-GAAP
ADJUSTED INFORMATION |
|
For the three months ended September 30,
2016 |
|
(in thousands) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
Cost of sales |
Research and development expense |
Selling, general and administrative
expense |
Amortization of intangible assets |
Interest expense |
Benefit from (provision for) income
taxes |
|
GAAP as
reported |
$ |
20,243 |
|
$ |
10,412 |
|
$ |
51,574 |
|
$ |
27,037 |
|
$ |
(20,307 |
) |
$ |
6,042 |
|
|
Non-cash interest expense on debt |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
4,460 |
|
|
- |
|
|
Intangible amortization related to product acquisitions |
|
- |
|
|
- |
|
|
- |
|
|
(27,037 |
) |
|
- |
|
|
- |
|
|
Contingent consideration related to product acquisitions |
|
- |
|
|
- |
|
|
(78 |
) |
|
- |
|
|
608 |
|
|
- |
|
|
Stock
based compensation |
|
(11 |
) |
|
(121 |
) |
|
(4,232 |
) |
|
- |
|
|
- |
|
|
- |
|
|
Other
costs |
|
- |
|
|
- |
|
|
(2,015 |
) |
|
- |
|
|
- |
|
|
- |
|
|
Income
tax effect of non-GAAP adjustments |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(13,479 |
) |
|
Non-GAAP
adjusted |
$ |
20,232 |
|
$ |
10,291 |
|
$ |
45,249 |
|
$ |
- |
|
$ |
(15,239 |
) |
$ |
(7,437 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
RECONCILATIONS OF GAAP REPORTED TO NON-GAAP
ADJUSTED INFORMATION |
|
For the nine months ended September 30,
2017 |
|
(in thousands) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
Product Sales |
Cost of sales |
Research and development expense |
Selling, general and administrative
expense |
Restructuring Charges |
Amortization of intangible assets |
Interest expense |
Benefit from (provision for) income
taxes |
|
GAAP as reported |
$ |
286,317 |
$ |
54,895 |
|
$ |
12,459 |
|
$ |
147,379 |
|
$ |
3,875 |
|
$ |
77,204 |
|
$ |
(55,697 |
) |
$ |
560 |
|
|
Non-cash
interest expense on debt |
|
- |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
15,613 |
|
|
- |
|
|
Managed
care dispute reserve |
|
4,742 |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
Intangible amortization related to product acquisitions |
|
- |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(77,204 |
) |
|
- |
|
|
- |
|
|
Contingent consideration related to product acquisitions |
|
- |
|
- |
|
|
- |
|
|
7,542 |
|
|
- |
|
|
- |
|
|
1,017 |
|
|
- |
|
|
Stock
based compensation |
|
- |
|
(84 |
) |
|
(652 |
) |
|
(9,134 |
) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
Other
costs |
|
- |
|
- |
|
|
- |
|
|
(3,142 |
) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
Restructuring charges |
|
- |
|
- |
|
|
- |
|
|
- |
|
|
(3,875 |
) |
|
- |
|
|
- |
|
|
- |
|
|
Valuation
allowance on deferred tax assets |
|
- |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
19,274 |
|
|
Income
tax effect of non-GAAP adjustments |
|
- |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(38,249 |
) |
|
Non-GAAP
adjusted |
$ |
291,059 |
$ |
54,811 |
|
$ |
11,807 |
|
$ |
142,645 |
|
$ |
- |
|
$ |
- |
|
$ |
(39,067 |
) |
$ |
(18,415 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RECONCILATIONS OF GAAP REPORTED TO NON-GAAP
ADJUSTED INFORMATION |
|
For the nine months ended September 30,
2016 |
|
(in thousands) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
Research and development expense |
Selling, general and administrative
expense |
Amortization of intangible assets |
Interest expense |
Benefit from (provision for) income
taxes |
|
GAAP as reported |
|
$ |
64,757 |
|
$ |
23,477 |
|
$ |
156,036 |
|
$ |
81,111 |
|
$ |
(63,182 |
) |
$ |
17,692 |
|
|
Non-cash
interest expense on debt |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
13,861 |
|
|
- |
|
|
Intangible amortization related to product acquisitions |
|
|
- |
|
|
- |
|
|
- |
|
|
(81,111 |
) |
|
- |
|
|
- |
|
|
Inventory
step-up related to product acquisitions |
|
|
(16 |
) |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
Contingent consideration related to product acquisitions |
|
|
- |
|
|
- |
|
|
209 |
|
|
- |
|
|
1,802 |
|
|
- |
|
|
Stock
based compensation |
|
|
(27 |
) |
|
(329 |
) |
|
(12,246 |
) |
|
- |
|
|
- |
|
|
- |
|
|
Other
costs |
|
|
- |
|
|
- |
|
|
(2,942 |
) |
|
- |
|
|
- |
|
|
- |
|
|
Income
tax effect of non-GAAP adjustments |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(39,211 |
) |
|
Non-GAAP
adjusted |
|
$ |
64,714 |
|
$ |
23,148 |
|
$ |
141,057 |
|
$ |
- |
|
$ |
(47,519 |
) |
$ |
(21,519 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
RECONCILIATION OF GAAP NET LOSS PER SHARE TO
NON-GAAP ADJUSTED EARNINGS PER SHARE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Nine Months Ended |
|
|
|
|
September 30, |
|
September 30, |
|
|
|
|
|
2017 |
|
|
|
2016 |
|
|
|
2017 |
|
|
|
2016 |
|
|
|
|
|
(unaudited) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net
loss per share |
|
$ |
(0.25 |
) |
|
$ |
(0.21 |
) |
|
$ |
(1.11 |
) |
|
$ |
(0.73 |
) |
|
|
Conversion from basic shares to diluted shares |
|
|
0.06 |
|
|
|
0.05 |
|
|
|
0.26 |
|
|
|
0.18 |
|
|
|
Non-cash interest expense on debt |
|
|
0.06 |
|
|
|
0.05 |
|
|
|
0.19 |
|
|
|
0.17 |
|
|
|
Managed care dispute reserve |
|
|
- |
|
|
|
- |
|
|
|
0.06 |
|
|
|
- |
|
|
|
Intangible amortization related to product acquisitions |
|
|
0.32 |
|
|
|
0.33 |
|
|
|
0.95 |
|
|
|
1.00 |
|
|
|
Inventory step-up related to product acquisitions |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
0.00 |
|
|
|
Contingent consideration related to product acquisitions |
|
|
(0.01 |
) |
|
|
0.01 |
|
|
|
(0.08 |
) |
|
|
0.02 |
|
|
|
Stock based compensation |
|
|
0.04 |
|
|
|
0.05 |
|
|
|
0.12 |
|
|
|
0.15 |
|
|
|
Other costs |
|
|
0.01 |
|
|
|
0.02 |
|
|
|
0.04 |
|
|
|
0.04 |
|
|
|
Restructuring charges |
|
|
0.01 |
|
|
|
- |
|
|
|
0.05 |
|
|
|
- |
|
|
|
Valuation allowance on deferred tax assets |
|
|
0.05 |
|
|
|
- |
|
|
|
0.24 |
|
|
|
- |
|
|
|
Income tax effect of non-GAAP adjustments |
|
|
(0.15 |
) |
|
|
(0.16 |
) |
|
|
(0.47 |
) |
|
|
(0.48 |
) |
|
|
Add interest expense of convertible debt, net of tax (2) |
|
|
0.02 |
|
|
|
0.02 |
|
|
|
0.03 |
|
|
|
0.03 |
|
|
|
Non-GAAP
adjusted earnings per share |
|
$ |
0.14 |
|
|
$ |
0.17 |
|
|
$ |
0.27 |
|
|
$ |
0.38 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depomed, Inc. (delisted) (NASDAQ:DEPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Depomed, Inc. (delisted) (NASDAQ:DEPO)
Historical Stock Chart
From Apr 2023 to Apr 2024